Caprisulin Log-G Dispopen

Insulin glargine

DM in adults, adolescents & childn ≥2 yr.

SC Individualized dosage. Administer once daily at any time but the same time each day. Inj sites must be rotated w/in given inj area from 1 inj to the next.

Hypersensitivity.

Not for IV administration. Not the insulin of choice for the treatment of diabetic ketoacidosis. Hyper- or hypoglycaemic episodes. Intensify blood glucose & metabolic monitoring. Caution in patients in whom hypoglycaemic episodes might be of clinical relevance (eg, patients w/ significant stenoses of the coronary arteries or of the blood vessels supplying the brain as well as in patients w/ proliferative retinopathy, particularly if not treated w/ photocoagulation; patients w/ diminished warning symptoms of hypoglycaemia (eg, patients in whom glycaemic control is markedly improved, in whom hypoglycaemia develops gradually, elderly, after transfer from animal to human insulin, in whom an autonomic neuropathy is present, w/ a long history of diabetes, suffering from a psychiatric illness, receiving concurrent treatment w/ certain other medical products). Prolonged effect may delay recovery from hypoglycaemia. Increased susceptibility to hypoglycaemia in case of change in inj area; improved insulin sensitivity; unaccustomed, increased or prolonged physical activity; intercurrent illness; inadequate food intake; missed meals; alcohol consumption; certain uncompensated endocrine disorders; concomitant treatment w/ certain other medical products. Hyperglycaemia may occur under certain circumstances including omission/reduction of inj or decrease in insulin effectiveness, pen malfunction; decreased physical activity, stress situations, injuries, operations, feverish illnesses or certain other diseases; concurrent use of other medicines. Intercurrent illness. Insulin label must always be checked before each inj to avoid medication errors. Insulin requirement may be diminished in patients w/ renal impairment or severe hepatic impairment. May impair ability to concentrate & react when driving or using machines. Maintain good metabolic control during pregnancy in women w/ preexisting or gestational diabetes. Decrease insulin requirements during 1st trimester & generally increase during 2nd & 3rd trimesters. Lactation. Childn <2 yr. Elderly.

Hypoglycaemia, temporary visual impairment, lipodystrophy, inj site & allergic reactions, formation of Insulin Ab.

Enhanced blood-glucose-lowering effect & increased susceptibility to hypoglycaemia w/ oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamide antibiotics. Reduced blood-glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, estrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones. Potentiated or weakened blood-glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Hypoglycemia may sometimes followed by hyperglycemia w/ pentamidine. Reduced or absent signs of adrenergic counter-regulation w/ sympatholytics eg, β-blockers, clonidine, guanethidine, reserpine.

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

G